PDF下载 ( 3653 KB)
口服肝靶向制剂介导受体ASBT和ASGPR在肝泡型包虫病大鼠模型体内的表达分析
DOI: 10.3969/j.issn.1001-5256.2021.04.024
利益冲突声明：本研究不存在研究者、伦理委员会成员、受试者监护人以及与公开研究成果有关的利益冲突。
作者贡献声明：高瑞雪、胡春晖、张发斌负责课题设计，撰写论文，修改论文；高瑞雪、高攀、甘雪辉、张耀刚、姜博璠参与收集数据及数据分析；高瑞雪、胡春晖、张发斌负责拟定写作思路，指导撰写文章并最后定稿。
Expression of ASBT and ASGPR mediated receptors for oral liver-targeting preparations in a rat model of hepatic alveolar echinococcosis
-
摘要:
目的 通过测定顶端钠依赖性胆盐转运体(ASBT)和去唾液酸糖蛋白受体(ASGPR)的表达研究，探讨其在肝泡型包虫病(HAE)药物治疗方面口服肝靶向制剂设计的可行性。 方法 18只雄性SD大鼠，10只大鼠造模，造模成功的8只大鼠为HAE组，正常组大鼠8只作为对照。采用免疫荧光、Western Blot、实时荧光定量PCR对ASBT在HAE模型大鼠及正常大鼠的回肠组织的表达分布、蛋白及基因表达水平进行检测分析；采用同样的检测方法分析ASGPR在HAE大鼠模型的非患病肝组织、肝组织病灶边缘带及正常大鼠肝组织的表达水平。符合正态分布的计量资料2组间比较采用t检验，3组间比较采用单因素方差分析，两两比较采用LSD-t检验。 结果 免疫荧光、Western Blot、实时荧光定量PCR结果均显示ASBT在HAE组回肠组织的表达较正常组表达上调(t值分别为5.309、4.110、28.060，P值均 < 0.05)。免疫荧光、Western Blot、实时荧光定量PCR结果均显示，ASGPR在正常对照组大鼠肝组织、HAE组大鼠非患病肝组织和HAE组大鼠肝织病灶边缘带中表达差异有统计学意义(F值分别为110.666、128.201、143.879，P值均 < 0.001)，其中HAE组较正常组表达水平高，且越靠近病灶组织表达越高。 结论 ASBT和ASGPR可作为HAE潜在的口服肝靶向制剂的介导受体，为设计用于治疗HAE的口服肝靶向制剂提供理论基础。 -
关键词:
- 棘球蚴病, 肝 /
- 分子靶向治疗 /
- 顶端钠依赖性胆盐转运体 /
- 去唾液酸糖蛋白受体 /
- 大鼠, Sprague-Dawley
Abstract:Objective To investigate the feasibility of apical sodium-dependent bile salt transporter (ASBT) and asialoglycoprotein receptor (ASGPR) in the design of oral liver-targeting preparations for the treatment of hepatic alveolar echinococcosis (HAE) by measuring the expression of ASBT and ASGPR. Methods A total of 18 male Sprague-Dawley rats were selected, among which 10 were used to establish a model of HAE (HAE group) and 8 were used as controls (normal group). Immunofluorescence assay, Western blotting, and quantitative real-time PCR were used to measure the expression distribution, protein expression level, and mRNA expression level of ASBT in the ileal tissue of HAE model rats and normal rats; the same methods were used to measure the expression level of ASGPR in the non-diseased liver tissue and the marginal zone of liver tissue lesion of HAE model rats and the liver tissue of normal rats. The t-test was used for comparison of normally distributed continuous data between two groups; a one-way analysis of variance was used for comparison between three groups, and the least significant difference t-test was used for comparison between two groups. Results The results of immunofluorescence assay, Western blotting, and quantitative real-time PCR showed that compared with the normal group, the HAE group had significantly upregulated expression of ASBT in the ileal tissue (t=5.309, 4.110, and 28.060, all P < 0.05) and a significantly higher expression level of ASGPR (the closer to the lesion, the higher the expression) (F=110.666, 128.201, and 143.879, all P < 0.001). Conclusion ASBT and ASGPR can be used as potential mediated receptors for oral liver-targeting preparations for HAE, which provides a theoretical basis for the design of oral liver-targeting preparations for the treatment of HAE. -
图 3 ASBT在正常大鼠及HAE大鼠回肠组织的表达分布(免疫荧光染色，×200)
注: DAPI，蓝色荧光(细胞核)；CY3，红色荧光(ASGPR阳性表达)；MERGE，叠加。
图 5 ASGPR在正常大鼠及HAE大鼠肝组织的表达分布(免疫荧光染色，×200)
注: DAPI，蓝色荧光(细胞核)；CY3，红色荧光(ASGPR阳性表达)；MERGE，叠加。
表 1 实时荧光定量PCR引物
靶基因 引物序列 ASBT Forward: 5′-TGCCGCCCTCCCCACAAC-3′ Reverse: 5′-GGACTGACCCTGGACTCTGACC-3′ ASGPR Forward: 5′-TGGCTGAGAGTCTGGCTTCCTG-3′ Reverse: 5′-AGTCATCTGGCTGCCCTGGTC-3′ β-actin Forward: 5′-CCTGGCACCCAGCACAAT-3′ Reverse: 5′-GCCGATCCACACGGAGTACT-3′ 
下载: 导出CSV
表 2 ASBT在正常大鼠及HAE大鼠的表达比较
组别 大鼠数(只) 免疫荧光面密度值(%) ASBT/β-actin mRNA相对表达量(2-△△CT) 正常对照组 8 1.286±0.261 0.331±0.025 0.988±0.031 HAE组 8 2.603±0.490 0.946±0.054 2.528±0.708 t值 5.309 4.110 28.060 P值 0.006 0.015 < 0.001
下载: 导出CSV
表 3 ASGPR在正常大鼠及HAE大鼠的表达比较
组别 大鼠数(只) 免疫荧光面密度值(%) ASBT/β-actin mRNA相对表达量(2-△△CT) 正常对照组大鼠肝组织 8 0.162±0.004 0.540±0.035 1.051±0.124 HAE组大鼠非患病肝组织 8 0.532±0.0691) 0.866±0.0831) 2.208±0.2331) HAE组大鼠肝组织病灶边缘带 8 1.275±0.1422) 1.024±0.0572) 3.808±0.5002) F值 110.666 128.201 143.879 P值 < 0.001 < 0.001 < 0.001 注：与正常大鼠肝组织相比, 1)P < 0.001；与HAE大鼠非患病肝组织相比, 2)P < 0.001。
下载: 导出CSV
-
[1] ROMIG T, EBI D, WASSERMANN M. Taxonomy and molecular epidemiology of Echinococcus granulosus sensu lato[J]. Vet Parasitol, 2015, 213(3-4): 76-84. DOI: 10.1016/j.vetpar.2015.07.035 [2] ZHANG W, ZHANG Z, WU W, et al. Epidemiology and control of echinococcosis in central Asia, with particular reference to the People's Republic of China[J]. Acta Trop, 2015, 141(Pt B): 235-243. http://smartsearch.nstl.gov.cn/paper_detail.html?id=ec4b630bb5cadfb9efc52d18b4fbd4f0 [3] ZHANG MY, WU WP, GUAN YY, et al. Analysis on disease burden of hydatid disease in China[J]. Chin J Parasitol Parasitic Dis, 2018, 36(1): 15-19, 25. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-ZJSB201801005.htm张梦媛, 伍卫平, 官亚宜, 等. 我国棘球蚴病疾病负担分析[J]. 中国寄生虫学与寄生虫病杂志, 2018, 36(1): 15-19, 25. https://www.cnki.com.cn/Article/CJFDTOTAL-ZJSB201801005.htm [4] AILIYALI AL, AYXAMGUL ALMS, GUO M, et al. Awareness rate of core knowledge of echinococcosis prevention and control in residents of Chinese farming and pastoral areas—meta-analysis[J]. Chin J Zoonoses, 2019, 35(2): 1144-1149. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-ZRSZ201912015.htm艾力亚力·艾力, 阿依谢姆古丽·阿力马斯, 郭敏, 等. 中国包虫病流行区居民包虫病防治知识知晓率—Meta分析[J]. 中国人兽共患病学报, 2019, 35(2): 1144-1149. https://www.cnki.com.cn/Article/CJFDTOTAL-ZRSZ201912015.htm [5] CHEN ZY. Surgical treatment of complicated liver hydatid disease[J]. Chin J Bases Clin Gen Surg, 2017, 24(7): 785-787. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-ZPWL201707001.htm陈哲宇. 复杂肝包虫病的外科治疗[J]. 中国普外基础与临床杂志, 2017, 24(7): 785-787. https://www.cnki.com.cn/Article/CJFDTOTAL-ZPWL201707001.htm [6] ABUDUAINI ABLZ, WEN H. Advances in multidisciplinary individualized treatment of refractory hepatic alveolar echinococcosis[J]. J Clin Hepatol, 2015, 31(4): 639-641. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2015.04.040阿卜杜艾尼·啊卜力孜, 温浩. 难治性肝泡型包虫病的多学科个体化治疗[J]. 临床肝胆病杂志, 2015, 31(4): 639-641. DOI: 10.3969/j.issn.1001-5256.2015.04.040 [7] CHAI JJ, MENGHEBT, JIAO W, et al. Clinical efficacy of albendazole emulsion in treatment of 212 cases of liver cystic hydatidosis[J]. Chin J Parasitol Parasitic Dis, 2001, 19(3): 3-8. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-ZJSB200103000.htm柴君杰, 孟贺巴特, 焦伟, 等. 阿苯达唑乳剂治疗肝囊型包虫病212例临床疗效观察[J]. 中国寄生虫学与寄生虫病杂志, 2001, 19(3): 3-8. https://www.cnki.com.cn/Article/CJFDTOTAL-ZJSB200103000.htm [8] ZHANG XN, ZHANG Q, WEN H, et al. Studies on preparation of albendazole polybutycyanocrylate nanoparticles and its stability[J]. Chin Pharmacol J, 2003, 38(5): 37-39. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYX200305013.htm张学农, 张强, 温浩, 等. 乳化聚合法制备阿苯达唑聚氰基丙烯酸酯纳米球的方法比较及稳定性考察[J]. 中国药学杂志, 2003, 38(5): 37-39. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYX200305013.htm [9] GUO F, DONG D, CHEN CZ, et al. Observation on nano albendazole against echinococcus granulosus protoscolices[J]. J Shihezi Univ(Natural Sci), 2018, 36(4): 482-485. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-SHZN201804014.htm郭峰, 董丹, 陈聪哲, 等. 纳米化阿苯达唑对细粒棘球蚴原头节生长的影响[J]. 石河子大学学报(自然科学版), 2018, 36(4): 482-485. https://www.cnki.com.cn/Article/CJFDTOTAL-SHZN201804014.htm [10] LI M, WANG Q, LI Y, et al. Apical sodium-dependent bile acid transporter, drug target for bile acid related diseases and delivery target for prodrugs: Current and future challenges[J]. Pharmacol Ther, 2020, 212: 107539. DOI: 10.1016/j.pharmthera.2020.107539 [11] FAN WW. Design of novel oral insulin nanocarriers to achieve highly efficient delivery in vivo and the underlying mechanism[D]. Shanghai: University of Chinese Academy of Sciences (Shanghai Institute of Materia Medica, Chinese Academy of Sciences), 2019. (in Chinese)范未伟. 胰岛素新型口服纳米载体的设计及其体内高效递送机制的研究[D]. 上海: 中国科学院大学(中国科学院上海药物研究所), 2019. [12] XUE Y, MA C, HANNA I, et al. Intestinal transporter-associated drug absorption and toxicity[J]. Adv Exp Med Biol, 2019, 1141: 361-405. http://www.ncbi.nlm.nih.gov/pubmed/31571170 [13] ZHANG Y, ZHANG X, ZENG C, et al. Targeted delivery of atorvastatin via asialoglycoprotein receptor (ASGPR)[J]. Bioorg Med Chem, 2019, 27(11): 2187-2191. DOI: 10.1016/j.bmc.2019.04.019 [14] WANG Z, XU J, WANG HJ, et al. Establishment of animal model for Echinococcus inoculation infection in Microtus fuscus in Qinghai-Tibet Plateau[J]. J Clin Hepatol, 2018, 34(2): 373-377. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2018.02.031王展, 胥瑾, 王海久, 等. 泡球蚴感染青藏高原野生田鼠动物模型的建立[J]. 临床肝胆病杂志, 2018, 34(2): 373-377. DOI: 10.3969/j.issn.1001-5256.2018.02.031 [15] MAIMAITI WSL, TUERGANAILI AJ. Research advances in surgical treatment of hepatic alveolar echinococcosis[J]. J Clin Hepatol, 2018, 34(3): 645-648. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2018.03.046买买提·瓦司力, 吐尔干艾力·阿吉. 肝泡型包虫病的手术治疗进展[J]. 临床肝胆病杂志, 2018, 34(3): 645-648. DOI: 10.3969/j.issn.1001-5256.2018.03.046 [16] MOVAHEDI F, LI L, GU W, et al. Nanoformulations of albendazole as effective anticancer and antiparasite agents[J]. Nanomedicine (Lond), 2017, 12(20): 2555-2574. DOI: 10.2217/nnm-2017-0102 [17] YIN J, FAN HN, WEN H, et al. Current status of the research and development of new formulations and drugs for cystic echinococcosis[J]. J Clin Hepatol, 2019, 35(4): 908-912. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.04.045尹杰, 樊海宁, 温浩, 等. 囊型包虫病药物新剂型研发及新药开发现状[J]. 临床肝胆病杂志, 2019, 35(4): 908-912. DOI: 10.3969/j.issn.1001-5256.2019.04.045 [18] CHAI J, MENGHEBAT, WEI J, et al. Observations on clinical efficacy of albendazole emulsion in 264 cases of hepatic cystic echinococcosis[J]. Parasitol Int, 2004, 53(1): 3-10. DOI: 10.1016/j.parint.2003.09.015 [19] LI H, SONG T, SHAO Y, et al. Comparative evaluation of liposomal albendazole and tablet-albendazole against hepatic cystic echinococcosis: A non-randomized clinical trial[J]. Medicine (Baltimore), 2016, 95(4): e2237. DOI: 10.1097/MD.0000000000002237 [20] LIU Y, WANG XQ, REN WX, et al. Novel albendazole-chitosan nanoparticles for intestinal absorption enhancement and hepatic targeting improvement in rats[J]. J Biomed Mater Res B Appl Biomater, 2013, 101(6): 998-1005. http://smartsearch.nstl.gov.cn/paper_detail.html?id=ac476a01c5990aa617c7d2a9088e6078 [21] CHATURVEDI K, GANGULYK, KULKARNI AR, et al. Oral insulin delivery using deoxycholic acid conjugated PEGylated polyhydroxybutyrate co-polymeric nanoparticles[J]. Nanomedicine (Lond), 2015, 10(10): 1569-1583. DOI: 10.2217/nnm.15.36 [22] LOZANO E, MONTE MJ, BRIZ O, et al. Enhanced antitumour drug delivery to cholangiocarcinoma through the apical sodium-dependent bile acid transporter (ASBT)[J]. J Control Release, 2015, 216: 93-102. DOI: 10.1016/j.jconrel.2015.08.022 [23] MONESTIER M, CHARBONNIER P, GATEAU C, et al. ASGPR-mediated uptake of multivalent glycoconjugates for drug delivery in hepatocytes[J]. Chembiochem, 2016, 17(7): 590-594. DOI: 10.1002/cbic.201600023 [24] D'SOUZA AA, DEVARAJAN PV. Asialoglycoprotein receptor mediated hepatocyte targeting-strategies and applications[J]. J Control Release, 2015, 203: 126-139. DOI: 10.1016/j.jconrel.2015.02.022 [25] WANG K, XU J, LIU Y, et al. Self-assembled Angelica sinensis polysaccharide nanoparticles with an instinctive liver-targeting ability as a drug carrier for acute alcoholic liver damage protection[J]. Int J Pharm, 2020, 577: 118996. DOI: 10.1016/j.ijpharm.2019.118996 [26] WU J, YUAN J, YE B, et al. Dual-responsive core crosslinking glycopolymer-drug conjugates nanoparticles for precise hepatocarcinoma therapy[J]. Front Pharmacol, 2018, 9: 663. DOI: 10.3389/fphar.2018.00663 -
本文二维码
图(6) / 表(3)
计量
- 文章访问数: 545
- HTML全文浏览量: 128
- PDF下载量: 28
- 被引次数: 0
